

# M T Nurmohamed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5398538/publications.pdf>

Version: 2024-02-01

176  
papers

9,443  
citations

50170

46  
h-index

40881

93  
g-index

179  
all docs

179  
docs citations

179  
times ranked

9667  
citing authors

#	ARTICLE	IF	CITATIONS
1	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	0.6	2
2	Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 129-136.	0.6	8
3	Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation. <i>Rheumatology International</i> , 2022, 42, 683-688.	1.5	7
4	Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001712.	1.8	3
5	COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2022, 4, e310-e313.	2.2	12
6	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
7	Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. <i>RMD Open</i> , 2022, 8, e002035.	1.8	11
8	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 597-599.	0.5	5
9	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429.	2.2	33
10	Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. <i>Journal of Clinical Medicine</i> , 2022, 11, 2704.	1.0	18
11	Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-5.	0.6	0
12	Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1196-1197.	0.5	3
13	Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1737-1745.	2.9	23
14	Are Health Care Professionals'™ Implicit and Explicit Attitudes Toward Conventional Disease-Modifying Antirheumatic Drugs Associated With Those of Their Patients?. <i>Arthritis Care and Research</i> , 2021, 73, 364-373.	1.5	3
15	The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2021, 41, 319-328.	1.5	17
16	Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 806-815.	2.9	15
17	Favorable effects on the hemostatic system in ankylosing spondylitis patients treated with golimumab. <i>Joint Bone Spine</i> , 2021, 88, 105102.	0.8	1
18	Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. <i>Lancet Rheumatology</i> , The, 2021, 3, e58-e70.	2.2	121

#	ARTICLE	IF	CITATIONS
19	Clinical improvement of cardiac function in a patient with systemic lupus erythematosus and heart failure with preserved ejection fraction treated with belimumab. <i>BMJ Case Reports</i> , 2021, 14, e237549.	0.2	5
20	Accuracy of an algorithm to identify rheumatoid arthritis in the Longitudinal Ageing Study Amsterdam population: a validation study. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 290-294.	0.6	2
21	Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. <i>RMD Open</i> , 2021, 7, e001591.	1.8	24
22	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 270-290.	3.5	57
23	Perspective of patients with autoimmune diseases on COVID-19 vaccination. <i>Lancet Rheumatology</i> , The, 2021, 3, e241-e243.	2.2	72
24	POS0669â€¦HYPOGLYCAEMIA FOLLOWING JAK INHIBITOR TREATMENT IN DIABETES MELLITUS PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 578-579.	0.5	2
25	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	1.0	2
26	POS0524â€¦CARDIOVASCULAR DISEASE RISK IN INFLAMMATORY ARTHRITIS PATIENTS STILL SUBSTANTIALLY ELEVATED IN 2020. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 495.2-496.	0.5	1
27	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 2352-2353.	2.9	0
28	Cardiorespiratory fitness and physical activity in people who have rheumatoid arthritis at an increased risk of cardiovascular disease: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 2177-2183.	1.5	6
29	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e778-e788.	2.2	130
30	Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e542-e545.	2.2	54
31	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-221146.	0.5	4
32	Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	1.0	0
33	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. <i>Osteoporosis International</i> , 2021, 32, 1441-1449.	1.3	4
34	The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patientsâ€”The CARDAS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5069.	1.0	10
35	Elevated Fab glycosylation of anti-hinge antibodies. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	0.6	3
36	Response to: "Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study" by Marotte et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e82-e82.	0.5	1

#	ARTICLE	IF	CITATIONS
37	The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2020, 59, 1703-1708.	0.9	8
38	Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period. <i>Clinical Rheumatology</i> , 2020, 39, 1521-1529.	1.0	10
39	The Effect of Anti-TNF Therapy on Cardiac Function in Rheumatoid Arthritis: An Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3145.	1.0	10
40	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology</i> , The, 2020, 2, e583-e585.	2.2	40
41	Cardiovascular risk in persons at risk of developing rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0237072.	1.1	10
42	Stakeholdersâ€™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1521-1528.	1.0	2
43	Response to: â€œInfluence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patientsâ€ by Fornaro et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e105-e105.	0.5	4
44	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. <i>Rheumatology</i> , 2020, 59, 1253-1261.	0.9	15
45	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	1.4	20
46	Immune-mediated inflammatory disease patientsâ€™ preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054.	1.0	6
47	Neutrophil activation identifies patients with active polyarticular gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 148.	1.6	14
48	A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15105.	0.5	19
49	245â€œRemission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors. <i>Rheumatology</i> , 2019, 58, .	0.9	2
50	Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence. <i>PLoS ONE</i> , 2019, 14, e0221290.	1.1	8
51	E064â€œThe relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme. <i>Rheumatology</i> , 2019, 58, .	0.9	3
52	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
53	Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 345-352.	0.6	15
54	Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 266-270.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Can personalized use of NSAIDs be a reality in the clinic?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 387-388.	3.5	0
56	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
57	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 610-616.	0.5	33
58	AB0733â€¦AN EYE FOR THE HEART: ARE RETINAL VASCULAR PARAMETERS ASSOCIATED WITH CARDIOVASCULAR DISEASE IN ANKYLOSING SPONDYLITIS?. , 2019, , .		0
59	Dietary Interventions for Gout and Effect on Cardiovascular Risk Factors: A Systematic Review. <i>Nutrients</i> , 2019, 11, 2955.	1.7	33
60	Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab â€” The GO-EASY Study. <i>Journal of Rheumatology</i> , 2019, 46, 153-159.	1.0	43
61	Noncanonical NF-Î²B signaling in microvessels of atherosclerotic lesions is associated with inflammation, atheromatous plaque morphology and myocardial infarction. <i>Atherosclerosis</i> , 2018, 270, 33-41.	0.4	26
62	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
63	Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 404-412.	3.7	56
64	Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 122-126.	0.6	10
65	The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis. <i>Biologics: Targets and Therapy</i> , 2018, Volume 12, 143-149.	3.0	3
66	Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 331-334.	0.4	11
67	Multicentric reticulohistiocytosis: a case report. <i>BMC Research Notes</i> , 2018, 11, 647.	0.6	3
68	Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. <i>PLoS ONE</i> , 2018, 13, e0205125.	1.1	14
69	Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance. <i>Clinical Rheumatology</i> , 2018, 37, 2151-2159.	1.0	7
70	2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1251-1260.	0.5	450
71	Editorial: Comorbidity Burden in Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 197.	1.2	13
72	An unfavorable body composition is common in early arthritis patients: A case control study. <i>PLoS ONE</i> , 2018, 13, e0193377.	1.1	19

#	ARTICLE	IF	CITATIONS
73	SP0087â€¦How to deal with cardiovascular risk factors for physical activity and implement the pa recommendations in the rheumatologic practice?. , 2018, , .		0
74	SAT0143â€¦The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy. , 2018, , .		0
75	Cardiovascular safety of celecoxib, naproxen and ibuprofen. Nature Reviews Rheumatology, 2017, 13, 136-138.	3.5	7
76	The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2017, 44, 1362-1368.	1.0	15
77	The Relationship Between Cardiac Conduction Times, Cardiovascular Risk Factors, and Inflammation in Patients with Early Arthritis. Journal of Rheumatology, 2017, 44, 580-586.	1.0	10
78	Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatology International, 2017, 37, 487-493.	1.5	146
79	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 2017, 76, 17-28.	0.5	918
80	Fat Mass Lowers the Response to Tumor Necrosis Factor-Î± Blockers in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2017, 44, 1355-1361.	1.0	18
81	Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-â€œadalimumab in patients with inflammatory diseases. British Journal of Clinical Pharmacology, 2017, 83, 2474-2484.	1.1	31
82	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology, 2017, 56, 1586-1596.	0.9	20
83	Brief Report: The Role of Rare Proteinâ€Coding Variants in Antiâ€Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 735-741.	2.9	8
84	Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. Scandinavian Journal of Rheumatology, 2017, 46, 87-94.	0.6	30
85	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. Arthritis Care and Research, 2017, 69, 989-996.	1.5	8
86	SP0127â€¦Tapering biologics induces a prothrombotic state in rheumatoid arthritis?. , 2017, , .		0
87	Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT. PLoS ONE, 2017, 12, e0181847.	1.1	13
88	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. RMD Open, 2017, 3, e000502.	1.8	3
89	OP0262â€¦Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial. Annals of the Rheumatic Diseases, 2016, 75, 157.2-157.	0.5	0
90	Effective Treatment for Rapid Improvement of Both Disease Activity and Selfâ€Reported Physical Activity in Early Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 280-284.	1.5	7

#	ARTICLE	IF	CITATIONS
91	Association of Somatic Comorbidities and Comorbid Depression With Mortality in Patients With Rheumatoid Arthritis: A 14-Year Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1055-1060.	1.5	27
92	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.5	179
93	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. <i>RMD Open</i> , 2016, 2, e000228.	1.8	15
94	Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 331-334.	0.6	10
95	Cardiovascular Disease Reduction in Rheumatoid Arthritis by Statins: The Final Evidence?. <i>Journal of Rheumatology</i> , 2016, 43, 1950-1952.	1.0	2
96	Cardiovascular disease in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 851-869.	1.4	95
97	THU0104...Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 217.1-217.	0.5	0
98	AB0265...Non-Canonical NF- $\kappa$ B Signaling in Microvessels of Atherosclerotic Lesions in Coronary Arteries Is Associated with Inflammatory Cell Infiltration and Myocardial Infarction. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 990.2-990.	0.5	0
99	THU0064...Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 201.1-201.	0.5	0
100	THU0062...Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 200.2-200.	0.5	0
101	Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1848-1851.	0.5	26
102	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2016, 18, 115.	1.6	30
103	The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1615-1622.	0.9	14
104	Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 758-764.	1.0	22
105	Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. <i>Heart</i> , 2016, 102, 790-795.	1.2	79
106	Comparing inflammatory cell density in the myocardium and coronary arteries in rheumatoid arthritis patients versus controls with myocardial infarction: A post-mortem case-control study. <i>International Journal of Cardiology</i> , 2016, 209, 74-76.	0.8	4
107	Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000080-e000080.	1.8	33
108	OP0013...Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 69.1-69.	0.5	0

#	ARTICLE	IF	CITATIONS
109	AB0287â€¦High Levels of 25(OH)D Are Associated with Lower Disease Activity in Patients with Newly Diagnosed Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2015, 74, 989.1-989.	0.5	0
110	Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. Journal of Immunological Methods, 2015, 418, 29-38.	0.6	70
111	Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24â€¦weeks of follow-up. Annals of the Rheumatic Diseases, 2015, 74, 396-401.	0.5	66
112	Editorial: Treat to Target in Rheumatoid Arthritis: Good for the Joints as Well as the Heart?. Arthritis and Rheumatology, 2015, 67, 1412-1415.	2.9	6
113	Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation. BMC Musculoskeletal Disorders, 2015, 16, 80.	0.8	22
114	Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24â€¦weeks of follow-up. Annals of the Rheumatic Diseases, 2015, 74, 1825-1829.	0.5	51
115	Objective Evaluation of Physical Functioning after Tumor Necrosis Factor Inhibitory Therapy in Patients with Ankylosing Spondylitis: A Selection of 3 Feasible Performance-based Tests. Journal of Rheumatology, 2015, 42, 623-629.	1.0	14
116	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders, 2015, 16, 176.	0.8	36
117	Cardiovascular comorbidity in rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 693-704.	3.5	260
118	Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis. Journal of Rheumatology, 2015, 42, 1842-1845.	1.0	17
119	Cardiovascular Disease-related Hospital Admissions of Patients with Inflammatory Arthritis. Journal of Rheumatology, 2015, 42, 188-192.	1.0	0
120	Key findings towards optimising adalimumab treatment: the concentrationâ€¦effect curve. Annals of the Rheumatic Diseases, 2015, 74, 513-518.	0.5	169
121	Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Annals of the Rheumatic Diseases, 2015, 74, 361-368.	0.5	81
122	TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits. PLoS ONE, 2015, 10, e0122271.	1.1	120
123	Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review. Current Medicinal Chemistry, 2015, 22, 1892-1902.	1.2	16
124	Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52â€¦weeks of follow-up. Annals of the Rheumatic Diseases, 2014, 73, 2178-2182.	0.5	70
125	Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology, 2014, 53, 2143-2154.	0.9	239
126	Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2014, 41, 1843-1848.	1.0	56



#	ARTICLE	IF	CITATIONS
127	A1.77â€¦Interferon regulatory factor 5 (IRF5) gene variant RS2004640 is associated with carotid intima media thickness in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A34.1-A34.	0.5	3
128	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 14.	0.8	44
129	Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 954-957.	0.5	68
130	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	3.5	154
131	Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2217-2219.	0.5	33
132	Response to: "The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis" by Gonzlez-Gayet al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e28-e28.	0.5	0
133	Is atherosclerosis an autoimmune disease?. <i>BMC Medicine</i> , 2014, 12, 47.	2.3	122
134	Biologics, cardiovascular effects and cancer. <i>BMC Medicine</i> , 2014, 12, 48.	2.3	14
135	Diastolic left ventricular dysfunction in ankylosing spondylitisâ€”A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 14-19.	1.6	32
136	Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e87965.	1.1	47
137	Cardiovascular risk management in rheumatoid arthritis: are we still waiting for the first step?. <i>Arthritis Research and Therapy</i> , 2013, 15, 111.	1.6	16
138	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 211-216.	0.5	224
139	Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study. <i>BMC Family Practice</i> , 2013, 14, 199.	2.9	31
140	Unresolved Questions in Rheumatology: Motion for Debate: The Data Support Evidenceâ€”Based Management Recommendations for Cardiovascular Disease in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1675-1683.	6.7	22
141	High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 825-830.	1.0	24
142	HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 560-565.	0.5	68
143	A5.30â€¦Systemic Inflammation and B-Cells in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A41.2-A41.	0.5	0
144	OP0002â€¦Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 52.2-52.	0.5	2

#	ARTICLE	IF	CITATIONS
145	Cardiovascular disease management in RA. Arthritis and Rheumatism, 2013, , n/a-n/a.	6.7	1
146	Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1915-1916.	0.5	20
147	Hypothyroidism in Rheumatoid Arthritis – To Screen or Not to Screen?. Journal of Rheumatology, 2012, 39, 885-886.	1.0	7
148	Management and evaluation of extra-articular manifestations in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 413-422.	1.2	49
149	Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1510-1516.	0.5	41
150	Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology, 2012, 8, 224-234.	3.5	118
151	Gastrointestinal Events in Rheumatoid Arthritis: Time for the Lower Gastrointestinal Tract!. Journal of Rheumatology, 2012, 39, 1317-1319.	1.0	2
152	Different Type of Carotid Arterial Wall Remodeling in Rheumatoid Arthritis Compared with Healthy Subjects: A Case-Control Study. Journal of Rheumatology, 2012, 39, 2261-2266.	1.0	18
153	Coexistence of hypothyroidism with inflammatory arthritis is associated with cardiovascular disease in women. Annals of the Rheumatic Diseases, 2012, 71, 1216-1218.	0.5	9
154	Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Annals of the Rheumatic Diseases, 2012, 71, 88-91.	0.5	121
155	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Annals of the Rheumatic Diseases, 2012, 71, 1950-1954.	0.5	91
156	Cardiovascular and Cerebrovascular Diseases in Ankylosing Spondylitis: Current Insights. Current Rheumatology Reports, 2012, 14, 415-421.	2.1	53
157	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis and Rheumatism, 2012, 64, 3850-3855.	6.7	68
158	Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. Clinical Rheumatology, 2012, 31, 1677-1682.	1.0	13
159	Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Annals of the Rheumatic Diseases, 2012, 71, 1914-1915.	0.5	196
160	Managing Cardiovascular Risk in Rheumatoid Patients. American Journal of Cardiology, 2012, 110, 763.	0.7	0
161	Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary care. BMC Musculoskeletal Disorders, 2012, 13, 150.	0.8	48
162	IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients. Journal of Clinical Immunology, 2012, 32, 1000-1006.	2.0	57

#	ARTICLE	IF	CITATIONS
163	Comorbidities in Patients with Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 523-538.	0.8	33
164	Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2012, 14, R52.	1.6	29
165	Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2012, 14, R95.	1.6	157
166	The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis. <i>Current Pharmaceutical Design</i> , 2012, 18, 1502-1511.	0.9	42
167	Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1460.	3.8	656
168	The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. <i>International Journal of Clinical Practice</i> , 2010, 64, 1440-1443.	0.8	49
169	Signs of Accelerated Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 161-166.	1.0	99
170	The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 38-41.	0.6	60
171	Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor $\alpha$ blockade. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 362-366.	0.5	101
172	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1571-1579.	6.7	318
173	Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRA% Investigation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1395-1400.	0.5	319
174	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 921-926.	0.5	492
175	Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. <i>Arthritis Research and Therapy</i> , 2006, 8, R151.	1.6	214
176	Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 585-592.	1.6	325